Chronic Heart Failure - COngestion eValuation

Condition(s) studied

Investigational drug(s) / intervention(s)

Clinical examination centered on congestion: Clinical examination (including the EVEREST, ASCEND and Ambrosy scores) centered on congestion will be performed during day hospitalization or consultation

Cardiac, pulmonary, peritoneal, jugular, renal Doppler ultrasounds and liver elastography: Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds will be performed during day hospitalization or consultation/ peritoneal, jugular and renal Doppler ultrasounds and liver elastography are optional

Blood sample retrieved for biological assessment and biobanking: Blood sample retrieved for biological assessment and biobanking will be performed during day hospitalization or consultation

Telephone follow-up: Telephone follow-up will be performed 3, 12 and 24 months after visit (during day hospitalization or consultation)

Kansas City Cardiomyopathy Questionnaire (KCCQ): Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge

Study summary

Heart failure (HF) is a significant cause of death and the leading cause of hospitalization in patients over 65 years of age. Congestion is the main source of symptoms and the leading cause of hospitalization for HF. Furthermore, congestive signs identified in asymptomatic patients are associated with the risk of developing symptomatic HF. The literature supports a multi-modality / integrative evaluation of congestion, combining clinical examination, laboratory results and ultrasound evaluation.

The main objective of the CHF-COV study is to identify congestion markers (clinical, biological and ultrasound) quantified during a consultation or day hospitalization for the monitoring of chronic HF that are associated with the risk of all-cause death or hospitalization for acute HF within 24 months after day hospitalization.

Eligibility

Primary outcome measure(s)

• Rate of death from all causes — 24 months after day hospitalization or consultation
  composite endpoint : rate of death from all causes or hospitalisation for acute heart failure during 24 months following day hospitalization (with outcome 2)
• Rate of hospitalisation for acute heart failure — 24 months after day hospitalization or consultation
  composite endpoint : rate of death from all causes or hospitalisation for acute heart failure during 24 months following day hospitalization (with outcome 1)

Trial sites (2)

More Pr. Nicolas GIRERD trials in France

Other trials for the same condition